Table 4. Literature overview of concurrent anti-EGFR agents and radiotherapy.
| Study | Phase | Patients N | EGFR+ N (%)* | RT (Gy) | Chemotherapy | PFS (med. m) | OS (med. m) | Toxicity >G4b (%) |
|---|---|---|---|---|---|---|---|---|
| Gefitinib | ||||||||
| Erlotinib | ||||||||
| Cetuximab | ||||||||
| Ready | II | PR:29 GR:21 | 13 (26) | 66 | PR: none GR: Conc Ca Txl | PR: 13.4 GR:9.2 | PR: 19 GR: 13 | PR:0 GR: G5 pneumonitis (8) G4 neutrop (36) |
| Niho | II | 38 | NS | 60 | Ind CDDP Vin | 11.2 | 28.5 | G4 HLE increase (6) |
| Stinchcombe | II | 23 | NS | 74 | Ind Ca Txl Iri Conc Ca Txl |
9 | 16 | G4 embolism (4.8) G4 thrombopenia (4.8) |
| Okamoto | II | 9 | 2 (29) | 60 | None | NS | NS | None |
| Center | I | 16 | NS | 70 | Conc+Cons Txt | 7.1 | 21 | G5 pneumonitis (13) |
| Rothschild | I | Step 1: 9 Step 2: 5 |
NS | 63 | Step 1 : none Step 2 : CDDP |
6m: 42.9% | 6m: 85.7% | G4 dyspnea (7) |
| Current | II | 16 | 0 | 66 | Cons CDDP Vin | 5 | 11 |
G5 pneumonitis (6.3) G4 pneumonia (6.3) G4 dehydration (6.3) |
| Lilenbaum | II | 75 | 0 | 66 | Ind Ca nab-Txl | 11 | 17 | G4 blood (8) G4 fatigue (1) |
| Komaki | II | 48 | 4 (8) | 63 | Conc+Cons Ca Txl | 14 | 36.5 | G4 pneumonitis (2) |
| Socinski | I/II | 45 | NS | 74 | Ind+Conc Ca Txl Bev+Cons Bev | 10.2 | 18.4 | G4 neutrop (18) G4 esophagitis (2) |
| Bradley | III | 147 110 |
NS | 60 74 |
Conc+Cons Ca Txl idem |
10.8 | 25 | G4 blood (46) G4/5 dyspnea (2) G4 pneumonitis (1) G4 dehydration (2) G4 dysphagia (1) |
| Blumenscheina | II | 93 | NS | 63 | Conc+Cons Ca Txl | 2y FR : 44.8% | 22.7 | G5 pneumonitis (2) G5 ARDS (1) |
| Hallqvist | II | 75 | NS | 68 | Ind CDDP Txt | NS | 17 | G5 pneumonitis (1.4) G4 hypersens (2.8) |
| Ramalingam | II | 40 | NS | 73.5 | Cons Ca Txl | 9.3 | 19.4 | G4 infection G4 infusion reaction G4 embolism G4 feb neutrop (9.8) |
| Govidan | II | 53 | NS | 70 | Conc Ca Pem | 12.3 | 25.2 | G5 pneumonitis (4) G5 embolism (2) |
N: number of; EGFR+ : epidermal growth factor receptor mutation; RT: radiotherapy; Conc: concurrent; Cons: Consolidation (post-RT); med. m: median months; PR: poor risk: GR: good risk; Ca: carboplatin: Txl: paclitaxel; Txt: docetaxel; Vin: vinorelbine; Bev: bevacizumab; Pem: pemetrexed; 6m: 6 month; neutrop: neutropenia; hypersens: hypersensitivity; HLE: hepatic liver enzymes; feb: febrile; ARDS: Acute respiratory distress syndrome; FR: failure rate; y: year; NS: not stated.
*Only genomic analyses are reported
a Only G5 are reported here for this study
b Only the concurrent period is generally reported